Trial Information
Blood Samples to Evaluate Biomarkers of Donor Chimerism
Inclusion Criteria:
- Diagnosed with a hematologic disease or malignancy
- Scheduled to receive nonablative conditioning with fludarabine and total body
irradiation
- Donor is well-matched by high resolution DNA techniques.
- Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an
oral calcineurin inhibitor.
- Age >18 years at the time of enrollment.
Exclusion criteria:
-Diagnosed with an immunodeficiency disorder
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Donor T-cell chimerism
Outcome Time Frame:
Day 28 post-transplant
Safety Issue:
No
Principal Investigator
Jeannine S McCune, PharmD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Institutional Review Board
Study ID:
FHCRC - 1980.00
NCT ID:
NCT00764829
Start Date:
September 2008
Completion Date:
February 2012
Related Keywords:
- Leukemia
- Hodgkins Disease
- Non-Hodgkins Lymphoma
- Myelodysplastic Syndrome
- hematopoietic stem cell transplantation
- fludarabine
- mycophenolate mofetil
- mycophenolic acid
- biomarkers
- Hodgkin Disease
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
Fred Hutchinson Cancer Research Center |
Seattle, Washington 98109 |